ICC results proclaimed that RFC4 expression was the highest among AML patients suffering Nrf2-low and non-mutated, while the lowest in the Nrf2-high and mutant groups (Fig. 2N). This evidence concerns the gene RFC4 and acute myeloid leukemia.